Antitumor Host Immunity Enhanced by Near-infrared Photoimmunotherapy

Overview

Journal Cancer Sci

Specialty Oncology

Date 2024 Dec 12

PMID 39663860

Authors

Hiroshi Fukushima

Aki Furusawa

Ryuhei Okada

Yasuhisa Fujii

Peter L Choyke

Hisataka Kobayashi

Affiliations

Soon will be listed here.

Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a novel antitumor therapy that selectively kills cancer cells by NIR light-triggered photochemical reaction of IRDye700DX within Ab-photoabsorber conjugates (APCs). NIR-PIT induces immunogenic cell death, causing immune cell migration between the tumor and tumor-draining lymph nodes, and expanding multiclonal tumor-infiltrating CD8 T cells. Crucially, the cytotoxic effects of NIR-PIT are limited to cancer cells, sparing immune cells such as antigen-presenting cells and T cells, which are key players in boosting antitumor host immunity. By modifying the Ab used in APC synthesis, NIR-PIT can be repurposed to target and deplete noncancerous immunosuppressive cells including regulatory T cells, myeloid-derived suppressor cells, and cancer-associated fibroblasts in the tumor microenvironment. Immunosuppressive cell targeted NIR-PIT strongly potentiates antitumor host immunity, including the induction of abscopal effects and the development of immune memory. Furthermore, antitumor immune responses and therapeutic efficacy are synergistically enhanced when NIR-PIT is combined with other immune-activating treatments, such as interleukin-15 and immune checkpoint inhibitors. These new findings make NIR-PIT a valuable tool in the evolving landscape of cancer immunotherapy. This review explains the role of NIR-PIT in activating antitumor host immunity.

Citing Articles

Photodynamic Therapy in Cancer: Insights into Cellular and Molecular Pathways.

Papa V, Furci F, Minciullo P, Casciaro M, Allegra A, Gangemi S Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996790 PMC: 11854756. DOI: 10.3390/cimb47020069.

Antitumor host immunity enhanced by near-infrared photoimmunotherapy.

Fukushima H, Furusawa A, Okada R, Fujii Y, Choyke P, Kobayashi H Cancer Sci. 2024; 116(3):572-580.

PMID: 39663860 PMC: 11875768. DOI: 10.1111/cas.16427.

References

Waldmann T, Miljkovic M, Conlon K . Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. J Exp Med. 2019; 217(1). PMC: 7037239. DOI: 10.1084/jem.20191062. View

Fukushima H, Furusawa A, Kato T, Wakiyama H, Takao S, Okuyama S . Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy. Mol Cancer Ther. 2023; 22(10):1215-1227. PMC: 10592297. DOI: 10.1158/1535-7163.MCT-23-0210. View

Ali H, Provenzano E, Dawson S, Blows F, Liu B, Shah M . Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014; 25(8):1536-43. DOI: 10.1093/annonc/mdu191. View

Shan F, Somasundaram A, Bruno T, Workman C, Vignali D . Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022; 8(11):944-961. PMC: 9588644. DOI: 10.1016/j.trecan.2022.06.008. View

Okada R, Maruoka Y, Furusawa A, Inagaki F, Nagaya T, Fujimura D . The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy. Bioconjug Chem. 2019; 30(10):2624-2633. PMC: 7413076. DOI: 10.1021/acs.bioconjchem.9b00547. View

Nagaya T, Nakamura Y, Okuyama S, Ogata F, Maruoka Y, Choyke P . Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody. Mol Cancer Res. 2017; 15(9):1153-1162. PMC: 5581714. DOI: 10.1158/1541-7786.MCR-17-0164. View

Hou Y, Yang X, Liu R, Zhao D, Guo C, Zhu A . Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles. Int J Nanomedicine. 2020; 15:6827-6838. PMC: 7501968. DOI: 10.2147/IJN.S269321. View

Pan H, Liu P, Zhao L, Pan Y, Mao M, Kroemer G . Immunogenic cell stress and death in the treatment of cancer. Semin Cell Dev Biol. 2023; 156:11-21. DOI: 10.1016/j.semcdb.2023.10.007. View

Wakiyama H, Furusawa A, Okada R, Inagaki F, Kato T, Maruoka Y . Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy. Cancers (Basel). 2020; 12(12). PMC: 7763141. DOI: 10.3390/cancers12123747. View

10.

Kong Y, Fuchsberger M, Xiang S, Apostolopoulos V, Plebanski M . Myeloid derived suppressor cells and their role in diseases. Curr Med Chem. 2013; 20(11):1437-44. DOI: 10.2174/0929867311320110006. View

11.

Sato K, Sato N, Xu B, Nakamura Y, Nagaya T, Choyke P . Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci Transl Med. 2016; 8(352):352ra110. PMC: 7780242. DOI: 10.1126/scitranslmed.aaf6843. View

12.

Kato T, Okada R, Furusawa A, Inagaki F, Wakiyama H, Furumoto H . Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. Mol Cancer Ther. 2021; 20(11):2262-2273. PMC: 10214494. DOI: 10.1158/1535-7163.MCT-21-0470. View

13.

Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Buque Martinez A . Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8(1). PMC: 7064135. DOI: 10.1136/jitc-2019-000337. View

14.

Wakiyama H, Furusawa A, Okada R, Inagaki F, Kato T, Furumoto H . Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers. Cancer Immunol Immunother. 2022; 71(12):2869-2879. PMC: 10673684. DOI: 10.1007/s00262-022-03205-5. View

15.

Walker L, Sansom D . The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11(12):852-63. DOI: 10.1038/nri3108. View

16.

Collins D, Bossenmaier B, Kollmorgen G, Niederfellner G . Acquired Resistance to Antibody-Drug Conjugates. Cancers (Basel). 2019; 11(3). PMC: 6468698. DOI: 10.3390/cancers11030394. View

17.

Kato T, Okada R, Furusawa A, Wakiyama H, Furumoto H, Fukushima H . Comparison of the Effectiveness of IgG Antibody versus F(ab') Antibody Fragment in CTLA4-Targeted Near-Infrared Photoimmunotherapy. Mol Pharm. 2022; 19(10):3600-3611. PMC: 10645141. DOI: 10.1021/acs.molpharmaceut.2c00242. View

18.

Okada R, Furusawa A, Inagaki F, Wakiyama H, Kato T, Okuyama S . Endoscopic near-infrared photoimmunotherapy in an orthotopic head and neck cancer model. Cancer Sci. 2021; 112(8):3041-3049. PMC: 8353912. DOI: 10.1111/cas.15013. View

19.

Okada R, Kato T, Furusawa A, Inagaki F, Wakiyama H, Choyke P . Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity. Adv Ther (Weinh). 2021; 4(5). PMC: 8115697. DOI: 10.1002/adtp.202000269. View

20.

Ogata F, Nagaya T, Okuyama S, Maruoka Y, Choyke P, Yamauchi T . Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy (3D LC-QPM) after treatment with the near infrared photoimmunotherapy. Oncotarget. 2017; 8(61):104295-104302. PMC: 5732807. DOI: 10.18632/oncotarget.22223. View